1. Home
  2. TSSI vs FHTX Comparison

TSSI vs FHTX Comparison

Compare TSSI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TSS Inc.

TSSI

TSS Inc.

HOLD

Current Price

$8.68

Market Cap

223.5M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.36

Market Cap

246.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSSI
FHTX
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.5M
246.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TSSI
FHTX
Price
$8.68
$4.36
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$11.86
AVG Volume (30 Days)
2.2M
198.0K
Earning Date
11-13-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
7.63
N/A
EPS
0.19
N/A
Revenue
$234,837,000.00
$24,518,000.00
Revenue This Year
N/A
$47.50
Revenue Next Year
N/A
N/A
P/E Ratio
$45.78
N/A
Revenue Growth
91.66
N/A
52 Week Low
$5.63
$2.95
52 Week High
$31.94
$7.42

Technical Indicators

Market Signals
Indicator
TSSI
FHTX
Relative Strength Index (RSI) 33.57 47.16
Support Level $8.60 $4.27
Resistance Level $9.48 $4.87
Average True Range (ATR) 0.74 0.38
MACD 0.20 -0.03
Stochastic Oscillator 53.05 7.77

Price Performance

Historical Comparison
TSSI
FHTX

About TSSI TSS Inc.

TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: